Abstract
Breast adenoid cystic carcinoma (AdCC) is a rare subtype of triple negative breast cancer. Two morphologic variants are described, namely classic AdCC (C-AdCC) and solid basaloid (SB-AdCC). Recent studies have shown that the SB-AdCC variant has significantly worse prognosis than C-AdCC. Due to the rarity of SB-AdCC, no standard recommendations are available for its management. Data on the use and benefit of chemotherapy in patients with SB-AdCC are sparse and the response to neoadjuvant chemotherapy has not been reported. We present the clinical and pathologic findings of a patient with SB-AdCC treated with neoadjuvant chemotherapy who achieved a remarkable pathologic response.
Cite
CITATION STYLE
Grabenstetter, A., Brogi, E., Zhang, H., Razavi, P., Reis-Filho, J. S., VanZee, K. J., … Wen, H. Y. (2022). Solid-basaloid variant of adenoid cystic carcinoma of the breast with near complete response to neoadjuvant chemotherapy. Npj Breast Cancer, 8(1). https://doi.org/10.1038/s41523-022-00469-z
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.